Antioxidant effect of virgin olive oil in patients with stable coronary heart disease: a randomized, crossover, controlled, clinical trial

2005 ◽  
Vol 181 (1) ◽  
pp. 149-158 ◽  
Author(s):  
M. Fitó ◽  
M. Cladellas ◽  
R. de la Torre ◽  
J. Martí ◽  
M. Alcántara ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Olive Oil ◽  
Virgin Olive Oil ◽  
Antioxidant Effect ◽  
Controlled Clinical Trial ◽  
Stable Coronary Heart Disease

scholarly journals Lifestyle and Treatment Adherence Intervention after a Coronary Event Based on an Interactive Web Application (EVITE): Randomized Controlled Clinical Trial Protocol

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1818
Author(s):  
MªÁngeles Bernal-Jiménez ◽  
Germán Calle-Pérez ◽  
Alejandro Gutiérrez-Barrios ◽  
Livia Gheorghe ◽  
Ana María Solano-Mulero ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Treatment Adherence ◽  
Coronary Event ◽  
Mobile Telephone ◽  
Analysis Of Covariance ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Randomized Controlled

Coronary heart disease is one of the main causes of morbimortality around the world. Patients that survive a coronary event suffer a high risk of readmission, relapse and mortality, attributed to the sub-optimal control of cardiovascular risk factors (CVRF), which highlights the need to improve secondary prevention strategies aimed at improving their lifestyle and adherence to treatment. Through a randomized controlled clinical trial, this study aims to evaluate the effect of an intervention involving an online health application supported by a mobile telephone or tablet (mHealth) on lifestyle (diet, physical activity, and tobacco consumption) and treatment adherence among people with coronary heart disease after percutaneous coronary intervention. The sample will comprise 240 subjects (120 in each arm: intervention and usual care). They are assessed immediately and nine months after their hospital discharge about sociodemographic, clinical, CVRF, lifestyle, and treatment adherence characteristics. The educative intervention, involving a follow-up and self-monitoring, will be performed using an online mHealth tool consisting of an application for mobile phones and tablets. The quantitative primary outcomes from the two groups will be compared using an analysis of covariance (ANCOVA) adjusted for age and gender. A multivariate analysis will be performed to examine the association of the intervention with lifestyle habits, the control of CVRFs, and outcomes after discharge in terms of the use of health services, emergency visits, cardiovascular events and readmissions.

scholarly journals Design and Methodology of a Multicenter Randomized Clinical Trial to Evaluate the Efficacy of Tongmai Jiangtang Capsules in Type 2 Diabetic Coronary Heart Disease Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Yu Wang ◽  
Yilei Guo ◽  
Ye Lei ◽  
Shuwei Huang ◽  
Liping Dou ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Vascular Complications ◽  
Complementary Therapy ◽  
Controlled Clinical Trial ◽  
Clinical Trial Registry ◽  
Clinical Trial Registration ◽  
Type 2 Diabetic

Background: Population-based studies have consistently showed an increased incidence of coronary heart disease and cardiac mortality in patients with type 2 diabetes mellitus (T2DM). Tongmai Jiangtang capsules (TJC) are Chinese patent medicines that have been approved in China for the treatment of diabetic vascular complications. However, the evidence supporting the efficacy of Tongmai Jiangtang capsules in type 2 diabetic coronary heart disease (T2DM-CHD) remains unclear. Herein, we designed a randomized, parallel-controlled clinical trial to investigate a new complementary therapy for T2DM-CHD patients.Methods: A total of 360 T2DM-CHD subjects (aged 18–75 years) will be randomly assigned to the TJC group or the placebo group at a 2:1 ratio. On the basis of western medicine therapy, all the participants will receive TJC or placebo, orally, three capsules/treatment, three per day for 12 weeks. The primary outcomes will be assessed according to the Canadian Cardiovascular Society (CCS) classification. All statistical analyses will be performed setting a two-sided 0.05 significance level, using SAS 9.4 statistical software.Discussion: The efficacy of TJC for the treatment of T2DM-CHD patients will be evaluated. The study will provide reliable clinical research evidence for application of TJC in treating T2DM-CHD patients.Clinical Trial Registration:https://www.chictr.org.cn/enIndex.aspx, Chinese Clinical Trial Registry ChiCTR2000037491.

scholarly journals Effect of voluntary breathing exercises on stable coronary artery disease in heart rate variability and rate-pressure product: a study protocol for a single blind, prospective randomized controlled trial

2019 ◽  
Author(s):  
Qing Wu ◽  
Lin Liu ◽  
Xin Jiang ◽  
Yao-Yao Hu ◽  
Qiu-Shi Liang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Heart Rate ◽  
Coronary Heart Disease ◽  
Heart Rate Variability ◽  
Oxygen Consumption ◽  
Heart Disease ◽  
Density Lipoprotein ◽  
Rate Pressure Product ◽  
Breathing Exercises ◽  
Stable Coronary Heart Disease

Abstract Background: At present, China has more than 11 million patients with stable coronary heart disease, becoming a major public health problem. The pathological changes of coronary heart disease can lead to dysfunction of cardiac autonomic nervous system, which increases the risk of complications such as malignant arrhythmia (ventricular flutter, ventricular fibrillation, etc.), heart rate, systolic blood pressure, and rate-pressure-product (RPP), which is highly correlated with myocardial oxygen consumption and indirectly reflects myocardial blood supply and oxygen consumption. Although the guidelines recommend that such patients take drugs to reduce heart rate and myocardial oxygen consumption, the clinical control of heart rate is still not ideal. Thus, in this trial, we will use voluntary breathing exercises as the strategy of exercise rehabilitation patients with SCAD, in order to increase the vagus nerve activity and/or reduce the sympathetic nervous activity, help maintain or rebuild the balance of plant nerve system, improve the time domain index of heart rate variability, reduce the burden on the heart, relieve patients' anxiety and other negative emotions. Methods: This is a 6 months single-blind, randomized controlled clinical trial that will be conducted in the First Affiliated Hospital of Soochow University. Eighty patients who fill out the Informed Consent Form are registered and randomized 1:1 into the VBE-based clinical trial monitoring group (n = 40) or the Routine follow-up group (n = 40). The VBE-based clinical trial monitoring group is given VBE training on the basis of conventional treatment and health education, while the control group received conventional health education and follow-up. The primary outcome will be measured heart rate variability (HRV) and rate-pressure product (RPP). Secondary outcomes will include changes in self-rating anxiety ccale (SAS), total cholesterol(TC), triglyceride (TG), high density lipoprotein (HDL-C),low density lipoprotein(LDL-C), weight and body mass index (BMI). Discussion: This trial will carry out scientific respiratory exercise for patients with stable coronary heart disease, which belongs to the category of active secondary prevention for patients, and changes from remedial to pre-protective. VBE is easy to operate, and is not limited by time and place. It is very important and meaningful to carry out VBE for patients with SCAD. This study will provide considerable evidence for further large-scale trials and alternative strategies for the rehabilitation nursing of patients with SCAD. Trial registration: This study is registered at Chinese Clinical Trials Registry.gov, ID:1900024043.Registered on 23 June 2019.

scholarly journals Effect of extra-virgin olive oil on lipid profile and inflammatory biomarkers in patients undergoing coronary angiography: a randomized, controlled, clinical trial

2020 ◽  
Author(s):  
Nafiseh Khandouzi ◽  
Ali Zahedmehr ◽  
Javad Nasrollahzadeh
Keyword(s):  
Clinical Trial ◽  
Cardiovascular Risk ◽  
Coronary Angiography ◽  
Olive Oil ◽  
Whole Blood ◽  
Ex Vivo ◽  
Virgin Olive Oil ◽  
Extra Virgin Olive Oil ◽  
Controlled Clinical Trial ◽  
Randomized Controlled

Abstract Background Olive oil, rich in mono-unsaturated fatty acid and the main fat in the Mediterranean diet, has long been considered to be favorable for cardiovascular health. The present study was conducted to compare the effects of high polyphenol extra-virgin olive oil (EVOO) with low polyphenol refined olive oil (ROO) on some cardiovascular risk factors in patients undergoing coronary angiography. Methods In a randomized, controlled, parallel-arm, clinical trial, 40 patients (aged 54.83 ± 7.04 years) with at least one classic cardiovascular risk factor (hypertension, dyslipidemia, or diabetes) who referred to coronary angiography were randomly allocated to two groups and received 25 mL EVOO (n = 20) or ROO (n = 20) daily for 6 weeks. Fasting blood was collected and plasma lipids, malondialdehyde (MDA), C-reactive protein (CRP) as well as, inflammatory cytokines in ex-vivo lipopolysaccharide (LPS)-stimulated whole blood culture were measured at the baseline and after the dietary intervention. Results Baseline characteristics were similar between the two groups. Plasma LDL-cholesterol significantly reduced in EVOO group (-9.52 ± 20.44 vs 8.68 ± 18.77 mg/dL, p = 0.007 for EVOO and ROO respectively), whereas total cholesterol/HDL-cholesterol had no significant changes. EVOO resulted in significant reduction in plasma CRP (-0.40 ± 0.52 vs 0.007 ± 0.42 mg/L, p = 0.01 for EVOO and ROO respectively) and increased ex-vivo whole blood LPS-stimulated IL-10 production (12.13 ± 33.64 vs -17.47 ± 49.04 pg/mL, p = 0.035 for EVOO and ROO respectively). However, there were no significant differences in LPS-stimulated IL-6 and plasma MDA levels between the two groups. Conclusions Daily consumption of polyphenol-rich EVOO in subjects who have been under medical treatment with risk-reducing agents could additionally improve LDL-C and selected inflammatory markers. Trial registration: NCT03796780 at clinicaltrial.gov (12/29/2018)

scholarly journals Protein Suppresses Both Bitterness and Oleocanthal-elicited Pungency of Extra Virgin Olive Oil

2021 ◽  
Author(s):  
Catherine Peyrot des Gachons ◽  
Abigail J. O’Keefe ◽  
Louise Slade ◽  
Gary K. Beauchamp
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Phenolic Compounds ◽  
Olive Oil ◽  
Virgin Olive Oil ◽  
Health Benefits ◽  
Extra Virgin Olive Oil ◽  
Sensory Loss ◽  
Sensory Receptors ◽  
The World

Abstract The Mediterranean diet, considered one of the healthiest in the world, is characterized in part by the major source of its fat, which is extra virgin olive oil (EVOO). Among the health benefits of consuming EVOOs is the presence of phenolic compounds, which have been shown to lower the incidence of coronary heart disease and are suspected of providing many other health benefits. These phenolic compounds also contribute to the flavor of EVOO, adding both pungent and bitter notes that are valued by connoisseurs but reported to be unpleasant by naïve consumers. Here, we demonstrate that some food-derived proteins, when added to pungent and bitter EVOOs, reduce or even eliminate both the pungency and bitterness. This sensory loss seems to be caused by the proteins binding the pungent phenolic compound, oleocanthal, as well as bitter tasting phenolics, leaving them unable to activate their respective sensory receptors (TRPA1 and TAS2Rs). Thus, when used in various foods recipes (e.g. mayonnaise), pungent and bitter EVOOs may lose their pungent and bitter characteristics thereby rendering them more palatable to many consumers. These data also raise the question of whether the bioactivities of EVOO phenolics remain unchanged when consumed with and without protein-containing foods.

Sign in / Sign up

Export Citation Format

Share Document